Virtual Library
Start Your Search
Wei Jiang
Author of
-
+
P09 - Health Services Research/Health Economics - Real World Outcomes (ID 121)
- Event: WCLC 2020
- Type: Posters
- Track: Health Services Research/Health Economics
- Presentations: 1
- Moderators:
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P09.01 - Different Administration Routes of Endostar Combined with Chemotherapy in the Treatment of Advanced NSCLC, a Real World Study (ID 2147)
00:00 - 00:00 | Presenting Author(s): Wei Jiang
- Abstract
Introduction
Recombinant human endostatin (endostar), an angiogenesis inhibitor, has been approved in combination with chemotherapy for the treatment of NSCLC in China. This study aims to evaluate real world efficacy and safety of endostar delivered by continuous intravenous pumping (CIV) or intravenous injection (IV) in combination with chemotherapy in the treatment of advanced NSCLC.
Methods
After obtaining ethical approval, this study retrospectively collected electronic medical record system (EMR) information of NSCLC patients (pts) who received endostar combined chemotherapy from June 2012 to August 2019 in 7 cancer hospitals. Baseline characteristics, efficacy evaluation and safety data were analyzed. According to the different administration routes of endostar, the patients were divided into IV group and CIV group. Tumor response was evaluated according to RECIST 1.1. Adverse events (AEs) were graded according to NCI-CTC AE 4.0. The endpoints include objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and safety.
Results
The EMR data of 1069 pts with advanced NSCLC who received endostar combined with chemotherapy were analyzed. 421 pts were assigned to IV group and 648 pts were assigned to CIV group. The median age of pts was 60 years. 71% was male, 69% was diagnosed at stage IV. 50% was adenocarcinoma and 31% was squamous cell carcinoma. 50% received endostar combined with chemotherapy as first-line. The ORRs, DCRs and median PFS of CIV and IV group were 30% vs. 32%, 52% vs. 61%, and 5.6 (95% CI 4.4-13.3) vs. 8.1 (95% CI 5.0-9.0) months, respectively (P>0.05). After matching baseline characteristics (gender, age, pathological type, chemotherapy regimen, dose intensity, etc.) using propensity scores, 98 people in each group were included in the analysis set. The median PFS of CIV and IV group were 8.5 months and 8.3 months, respectively (HR=0.99, P=0.96). The most common AEs in CIV and IV group were gastrointestinal reactions (29% vs 27%), bone marrow suppression (24% vs 30%), and liver damage (9% vs 13%), with no significant difference between the two groups.
Conclusion
Real world data demonstrated no significant differences in the efficacy and safety of endostar delivered by CIV or IV in combination with chemotherapy in the treatment of advanced NSCLC. In addition to IV, CIV is potentially an alternative administration route for endostar.
